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There is increasing evidence that myeloid-derived sup-
pressor cells (MDSCs) contribute to the progression of
cancer by inhibiting tumor-directed immune responses
and producing mediators that promote the growth and
survival of tumor cells. While present at low numbers in
the peripheral blood of healthy individuals, levels of cir-
culating MDSC increase in cancer patients as tumors
produce factors that drive both the expansion and
recruitment of these cells. MDSCs are a heterogeneous
population and include both granulocytic MDSC (G-
MDSC) and monocytic MDSC (M-MDSC) sub-popula-
tions, each of which can inhibit T cell function through
arginase activity and the production of nitric oxide.
Novel approaches to decrease MDSC expansion or inhi-
bit their immunosuppressive functions hold great pro-
mise for augmenting tumor directed immune responses.
In this study, we examined the effect of motolimod (for-
merly VTX-2337), a selective TLR8 agonist, on MDSC
function. Initially TLR8 mRNA levels were assessed in
MDSC isolated from the peripheral blood of healthy
donors. TLR8 mRNA levels found in the M-MDSC sub-
population were comparable to those found in mono-
cytes and myeloid dendritic cells (mDC), which express
high levels of TLR8 protein and activate in response to
motolimod. To further assess the M-MDSC response to
TLR8 activation, PBMCs from healthy donors were trea-
ted with medium alone, low dose (167 nM), or high
dose (500 nM) motolimod. Treatment with motolimod
resulted in a significant, concentration–dependent loss
of the M-MDSC (HLA-DR-CD14+) sub-population. In
contrast, there was no significant difference in the
recovery of the G-MDSC subtype (Lin-HLA-DR-CD33+)
following motolimod treatment. Additionally, treatment
with either the TLR7 agonist imiquimod, or TLR9 ago-
nist CpG ODN2006, did not result in a loss of the
M-MDSC population. The decrease in M-MDSC popu-
lation was found to be the result of these cells under-
going apoptosis following motolimod treatment.
M-MDSCs were also found to increase FAS expression
in response to TLR8 activation by motolimod. Studies
to determine if motolimod can decrease the immuno-
suppressive and/or tumor-promoting activities of MDSC
sub-populations are ongoing. Our finding, that TLR8-
activated m-MDSCs undergo apoptosis, suggests the
potential for using motolimod to modulate MDSC num-
bers and function in cancer patients and enable a more
effective, immune response to tumors. This innovative
approach for modulating m-MDSC populations holds
great promise for augmenting anti-tumor directed
immune responses.
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